XML 36 R23.htm IDEA: XBRL DOCUMENT
v3.26.1

SEGMENT AND ENTERPRISE-WIDE INFORMATION | 3 Months Ended
--- | ---
Jun. 27, 2026
Segment Reporting [Abstract] |
SEGMENT AND ENTERPRISE-WIDE INFORMATION | 16. SEGMENT AND ENTERPRISE-WIDE INFORMATION On June 5, 2026, the Company implemented an organizational realignment designed to align its commercial operations into two global reportable segments by combining the previously reported Plasma and Blood Center reportable segments into Apheresis and renaming the Hospital reportable segment to MedSurg. This organizational structure reflects how the Company is organized to manage operations, allocate resources and evaluate performance. As a result, the information that is regularly reviewed by the Company’s chief operating decision maker (“CODM”), identified as the Chief Executive Officer, has changed. Prior-period segment information presented has been recast to reflect the current reportable segment structure. The Company’s reportable and operating segments are as follows: •Apheresis •MedSurg The CODM measures and evaluates the operating segments based on operating income for purposes of assessing business performance and allocating resources. The CODM uses segment operating income for each segment by comparing on a quarterly basis actual results to the prior year comparable period and to the annual operating plan to assess the performance of the segments and to allocate resources across our segments. Certain corporate expenses and amounts considered to be non-recurring or non-operational are excluded from segment operating income. These items include restructuring costs, restructuring related costs, digital transformation costs, amortization of acquired intangible assets, amortization of fair value inventory step-up, acquisition, integration and divestiture related costs, unusual or infrequent and material litigation-related charges, and remeasurement of contingent consideration. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. The Company does not track its total assets by segment. Consequently, the Company’s CODM does not review total assets by segment when assessing business performance and allocating resources. Selected information by reportable segment is presented below:
| Three Months Ended |  |
| June 27, 2026 |  | June 28, 2025 |  |  |  |
| (Dollars in Thousands)
Net revenues: |  |  |  |  |  |  |
Apheresis | $ | 191,318 |  |  | $ | 181,736 |  |  |  |  |
MedSurg | 148,062 |  |  | 139,658 |  |  |  |  |
Total net revenues | $ | 339,380 |  |  | $ | 321,394 |  |  |  |  |
Significant segment expenses and operating performance: |  |  |  |  |  |  |
Apheresis |  |  |  |  |  |  |
Cost of goods sold | $ | 84,131 |  |  | $ | 75,865 |  |  |  |  |
Selling, general and administrative | 44,264 |  |  | 39,880 |  |  |  |  |
Research and development | 6,378 |  |  | 6,816 |  |  |  |  |
Apheresis operating income | $ | 56,545 |  |  | $ | 59,175 |  |  |  |  |
MedSurg |  |  |  |  |  |  |
Cost of goods sold | $ | 50,368 |  |  | $ | 50,216 |  |  |  |  |
Selling, general and administrative | 65,160 |  |  | 62,323 |  |  |  |  |
Research and development | 9,820 |  |  | 8,742 |  |  |  |  |
MedSurg operating income | $ | 22,714 |  |  | $ | 18,377 |  |  |  |  |
Corporate and unallocated expenses |  |  |  |  |  |  |
Amortization of acquired assets | $ | (10,204) |  |  | $ | (13,828) |  |  |  |  |
Integration and transaction costs | (2,719) |  |  | (2,682) |  |  |  |  |
Restructuring and restructuring related costs | (2,258) |  |  | (1,324) |  |  |  |  |
Digital transformation costs | (6,163) |  |  | (5,355) |  |  |  |  |
Other(1) | (457) |  |  | (491) |  |  |  |  |
Operating income | 57,458 |  |  | 53,872 |  |  |  |  |
Interest and other expense, net | (9,884) |  |  | (8,703) |  |  |  |  |
Income before provision for income taxes | $ | 47,574 |  |  | $ | 45,169 |  |  |  |  |
__________ (1) Comprised of litigation-related charges and remeasurement of contingent consideration for the three months ended June 27, 2026 and June 28, 2025. Net revenues by business unit are as follows:
|  |  | Three Months Ended
|  |  |  |  | June 27, 2026 |  | June 28, 2025
|  |  |  |  | (Dollars in Thousands)
Apheresis |  |  |  |  |  |  |
Plasma |  |  |  |  | $ | 155,524 |  |  | $ | 145,074 |
Other |  |  |  |  | 35,794 |  |  | 36,662 |
Apheresis net revenues |  |  |  |  | $ | 191,318 |  |  | $ | 181,736 |
MedSurg |  |  |  |  |  |  |
Interventional Technologies |  |  |  |  | $ | 59,942 |  |  | $ | 58,483 |
Blood Management Technologies |  |  |  |  | 88,120 |  |  | 81,175 |
MedSurg net revenues |  |  |  |  | $ | 148,062 |  |  | $ | 139,658 |
Total net revenues |  |  |  |  | $ | 339,380 |  |  | $ | 321,394 |
Depreciation and amortization, excluding impairment charges, by business unit are as follows:
|  |  | Three Months Ended
|  |  |  |  | June 27, 2026 |  | June 28, 2025
|  |  |  |  | (Dollars in Thousands)
Apheresis |  |  |  |  | $ | 13,631 |  |  | $ | 13,912 |
MedSurg |  |  |  |  | 13,480 |  |  | 14,846 |
Total depreciation and amortization (excluding impairment charges) |  |  |  |  | $ | 27,111 |  |  | $ | 28,758 |
Long-lived assets, comprised of property, plant and equipment, by business unit are as follows:
| June 27, 2026 |  | March 28, 2026
| (Dollars in Thousands)
Apheresis | $ | 244,089 |  |  | $ | 246,042 |
MedSurg | 59,689 |  |  | 59,719 |
Total long-lived assets | $ | 303,778 |  |  | $ | 305,761 |
Long-lived assets, comprised of property, plant and equipment, by operating regions are as follows:
| June 27, 2026 |  | March 28, 2026
| (Dollars in Thousands)
United States | $ | 223,004 |  |  | $ | 224,699 |
Japan | 882 |  |  | 916 |
Europe | 32,293 |  |  | 32,080 |
Rest of Asia | 30,010 |  |  | 30,833 |
Other | 17,589 |  |  | 17,233 |
Total long-lived assets | $ | 303,778 |  |  | $ | 305,761 |
Net revenues by operating regions are as follows:
|  |  | Three Months Ended
|  |  |  |  | June 27, 2026 |  | June 28, 2025
|  |  |  |  | (Dollars in Thousands)
United States |  |  |  |  | $ | 257,844 |  |  | $ | 242,404 |
Japan |  |  |  |  | 12,858 |  |  | 13,648 |
Europe |  |  |  |  | 45,529 |  |  | 40,882 |
Rest of Asia |  |  |  |  | 20,163 |  |  | 21,648 |
Other |  |  |  |  | 2,986 |  |  | 2,812 |
Total net revenues |  |  |  |  | $ | 339,380 |  |  | $ | 321,394 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for segment reporting. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 18: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 19: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 20: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 21: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 22: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration